News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Celgene European Panel Recommends Against Revlimid for MDS
January 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Jan 24 (Reuters) - Celgene Corp said on Thursday an advisory panel for European health regulators recommended Revlimid not be approved in Europe for myelodysplastic syndrome patients with anemia, citing safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Legal
Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus
February 18, 2026
·
2 min read
·
Tristan Manalac
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
CDC
CDC Left Leaderless Again After Acting Director Departs HHS
February 16, 2026
·
1 min read
·
Tristan Manalac
